- Home
- Publications
- Publication Search
- Publication Details
Title
Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
Authors
Keywords
-
Journal
Molecular Cancer
Volume 18, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-06
DOI
10.1186/s12943-019-1091-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer
- (2019) Jorge Blando et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
- (2019) Jun Wang et al. NATURE MEDICINE
- Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution
- (2019) Veronica Mollica et al. CLINICAL DRUG INVESTIGATION
- AIPAC: a Phase IIb study of eftilagimod alpha (IMP321 or LAG-3Ig) added to weekly paclitaxel in patients with metastatic breast cancer
- (2019) Luc Dirix et al. Future Oncology
- Characterization of a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody for cancer immunotherapy
- (2019) Xiaojie Yu et al. mAbs
- Immune checkpoints in the tumor microenvironment
- (2019) Salman M. Toor et al. SEMINARS IN CANCER BIOLOGY
- Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia
- (2018) Marina Wierz et al. BLOOD
- PD-1 blockade in advanced NSCLC: A focus on pembrolizumab
- (2018) Solange Peters et al. CANCER TREATMENT REVIEWS
- PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene
- (2018) Kristin Nicole Berger et al. GENE
- Gut microbiome modulates efficacy of immune checkpoint inhibitors
- (2018) Ming Yi et al. Journal of Hematology & Oncology
- Next generation of immune checkpoint therapy in cancer: new developments and challenges
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial
- (2018) Mark M Souweidane et al. LANCET ONCOLOGY
- Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
- (2018) Qing Zhang et al. NATURE IMMUNOLOGY
- Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy
- (2018) Bo Zhu et al. ONCOGENE
- TIGIT: a novel immunotherapy target moving from bench to bedside
- (2018) Benjamin L. Solomon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- VSIG-3 as a ligand of VISTA inhibits human T cell function
- (2018) Jinghua Wang et al. IMMUNOLOGY
- A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers.
- (2018) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
- (2018) Jun Wang et al. CELL
- The 2018 Nobel Prize in Physiology or Medicine: An exemplar of bench to bedside in immunology
- (2018) Zuhair K. Ballas JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Tim-3 expression and its role in hepatocellular carcinoma
- (2018) Feifei Liu et al. Journal of Hematology & Oncology
- Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing
- (2018) Zihai Li et al. Journal of Hematology & Oncology
- TSR-033, a novel therapeutic antibody targeting LAG-3 enhances T cell function and the activity of PD-1 blockade in vitro and in vivo
- (2018) Srimoyee Ghosh et al. MOLECULAR CANCER THERAPEUTICS
- TIM-3, a promising target for cancer immunotherapy
- (2018) Yayi He et al. OncoTargets and Therapy
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3
- (2017) Murali Janakiram et al. IMMUNOLOGICAL REVIEWS
- Immunoregulatory functions of VISTA
- (2017) Elizabeth C. Nowak et al. IMMUNOLOGICAL REVIEWS
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy
- (2017) William C. Dougall et al. IMMUNOLOGICAL REVIEWS
- The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
- (2017) Andrew W Hahn et al. Immunotherapy
- Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
- (2017) Jean-Sebastien Frenel et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
- (2017) Jun Wang et al. Journal of Hematology & Oncology
- Recent advances of bispecific antibodies in solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Chimeric antigen receptor T cells: a novel therapy for solid tumors
- (2017) Shengnan Yu et al. Journal of Hematology & Oncology
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody
- (2016) A. Murtaza et al. EUROPEAN JOURNAL OF CANCER
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis
- (2016) B Benzon et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Pathological -synuclein transmission initiated by binding lymphocyte-activation gene 3
- (2016) X. Mao et al. SCIENCE
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Pembrolizumab (Keytruda)
- (2016) Gerry Kwok et al. Human Vaccines & Immunotherapeutics
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
- (2016) Ruea-Yea Huang et al. OncoImmunology
- Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial
- (2015) A. Legat et al. CLINICAL CANCER RESEARCH
- Binding of the Fap2 Protein of Fusobacterium nucleatum to Human Inhibitory Receptor TIGIT Protects Tumors from Immune Cell Attack
- (2015) Chamutal Gur et al. IMMUNITY
- Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3
- (2015) Mahiuddin Ahmed et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- TIGIT predominantly regulates the immune response via regulatory T cells
- (2015) Sema Kurtulus et al. JOURNAL OF CLINICAL INVESTIGATION
- Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
- (2015) Ninh M. La-Beck et al. PHARMACOTHERAPY
- Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
- (2015) Chiao-Wen Kang et al. Scientific Reports
- Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells
- (2015) T. Kouo et al. Cancer Immunology Research
- Beyond CTLA-4 and PD-1, the Generation Z of Negative Checkpoint Regulators
- (2015) Isabelle Le Mercier et al. Frontiers in Immunology
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- VISTA Is an Immune Checkpoint Molecule for Human T Cells
- (2014) J. L. Lines et al. CANCER RESEARCH
- VISTA Regulates the Development of Protective Antitumor Immunity
- (2014) I. Le Mercier et al. CANCER RESEARCH
- LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses
- (2014) F. Xu et al. CANCER RESEARCH
- T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling
- (2014) Man Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial
- (2014) Emanuela Romano et al. Journal of Translational Medicine
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR
- (2013) Noa Stanietsky et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- B7 family checkpoint regulators in immune regulation and disease
- (2013) Sabrina Ceeraz et al. TRENDS IN IMMUNOLOGY
- Harnessing the Power of the Immune System to Target Cancer
- (2012) Gregory Lizée et al. Annual Review of Medicine
- Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells
- (2012) S Liu et al. CELL DEATH AND DIFFERENTIATION
- Tim-3, a negative regulator of anti-tumor immunity
- (2012) Ana Carrizosa Anderson CURRENT OPINION IN IMMUNOLOGY
- A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma
- (2012) Andrea Wang-Gillam et al. INVESTIGATIONAL NEW DRUGS
- The TIGIT/CD226 Axis Regulates Human T Cell Function
- (2012) E. Lozano et al. JOURNAL OF IMMUNOLOGY
- Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
- (2012) Shigeki Chiba et al. NATURE IMMUNOLOGY
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Ipilimumab
- (2011) Fiona Cameron et al. DRUGS
- Vstm3 is a member of the CD28 family and an important modulator of T-cell function
- (2011) Steven D. Levin et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation
- (2011) Marcos W. Steinberg et al. IMMUNOLOGICAL REVIEWS
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
- (2011) N. Joller et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models
- (2011) D. B. Flies et al. JOURNAL OF IMMUNOLOGY
- Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker
- (2011) M. Jan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion
- (2010) Xiaoyuan Huang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
- (2010) Chrystelle Brignone et al. Journal of Translational Medicine
- Tim-3 mediates phagocytosis of apoptotic cells and cross-presentation
- (2009) M. Nakayama et al. BLOOD
- A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
- (2009) C. Brignone et al. CLINICAL CANCER RESEARCH
- A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC
- (2009) Kent S. Boles et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- CD28 and CTLA-4 coreceptor expression and signal transduction
- (2009) Christopher E. Rudd et al. IMMUNOLOGICAL REVIEWS
- Mechanisms of costimulation
- (2009) Arlene H. Sharpe IMMUNOLOGICAL REVIEWS
- Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
- (2009) Kim Kramer et al. JOURNAL OF NEURO-ONCOLOGY
- The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
- (2009) N. Stanietsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator
- (2008) Guifang Cai et al. NATURE IMMUNOLOGY
- The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
- (2008) Xin Yu et al. NATURE IMMUNOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started